Huang, S., Lin, H., Zhu, X., et al. (2014) Zoledronic Acid Increases Bone Mineral Density and Improves Health-Related Quality of Life over Two Years of Treatment in Chinese Women with Postmenopausal Osteoporosis. Endokrynologia Polska, 65, 96-104.
 Gauthier, K., Bai, A., Perras, C., et al. (2012) Denosumab, Raloxifene, and Zoledronic Acid for the Treatment of Postmenopausal Osteoporosis: Clinical Effectiveness and Harms. Canadian Agency for Drugs and Technologies in Health, Ottawa, ON.
 Nishizawa, Y., Ohta, H., Miura, M., et al. (2013) Guidelines for the Use of Bone Metabolic Markers in the Diagnosis and Treatment of Osteoporosis. Journal of Bone and Mineral Metabolism, 31, 1-15.
 Cavalier, E., Bergmann, P., Bruyere, O., et al. (2016) The Role of Biochemical of Bone Turnover Markers in Osteoporosis and Metabolic Bone Disease: A Consensus Paper of the Belgian Bone Club. Osteoporosis International, 27, 2181-2195.
 Ruza, I., Mirfakhraee, S., Orwoll, E., et al. (2013) Clinical Experience with Intravenous Zoledronic Acid in the Treatment of Male Osteoporosis: Evidence and Opinions. Therapeutic Advances in Musculoskeletal Disease, 5, 182-198.
 Tasci, I., Safer, U., Cintosun, U., et al. (2016) Zoledronic Acid Use and Risk of Cognitive Decline among Elderly Women and Men with Osteoporosis. Endocrine, Metabolic & Immune Disorders Drug Targets, 16, 32-38.
 Gamsjaeger, S., Buchinger, B., Zwettler, E., et al. (2011) Bone Material Properties in Actively Bone-Forming Trabeculae in Postmenopausal Women with Osteoporosis after Three Years of Treatment with Once-Yearly Zoledronic Acid. Journal of Bone and Mineral Research, 26, 12-18.
 Sheedy, K.C., Camara, M.I. and Camacho, P.M. (2015) Comparison of the Efficacy, Adverse Effects, and Cost of Zoledronic Acid and Denosumab in the Treatment of Osteoporosis. Endocrine Practice, 21, 275-279.
 Carmona, R. and Adachi, R. (2009) Treatment of Postmenopausal Osteoporosis, Patient Perspectives—Focus on Once Yearly Zoledronic Acid. Patient Preference and Adherence, 3, 189-193.
 Wang, C. (2017) Efficacy and Safety of Zoledronic Acid for Treatment of Postmenopausal Osteoporosis: A Meta-Analysis of Randomized Controlled Trials. American Journal of Therapeutics, 24, e544-e552.
 Cremers, S. and Garnero, P. (2006) Biochemical Markers of Bone Turnover in the Clinical Development of Drugs for Osteoporosis and Metastatic Bone Disease: Potential Uses and Pitfalls. Drugs, 66, 2031-2058.